Screener
Ginkgo Bioworks DNA EPS (Diluted)
Discontinued — last reported Q4 '25
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Ginkgo Bioworks’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:34 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-012346
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Loss before income taxes | (313,600) | (547,508) | (892,940) |
| Income tax benefit | (837) | (479) | (71) |
| Net loss | $(312,763) | $(547,029) | $(892,869) |
| Net loss per share | $(5.64) | $(10.54) | $(18.37) |
| Weighted average common shares outstanding: | 55,457,676 | 51,894,639 | 48,610,507 |
| Comprehensive loss: | |||
| Net loss | $(312,763) | $(547,029) | $(892,869) |
| Other comprehensive income (loss): |
Item 16. Form 10-K Summary
FAQ
- What is Ginkgo Bioworks's EPS (diluted)?
- Ginkgo Bioworks (DNA) reported EPS (diluted) of -$1.42 in Q4 2025.
- How has Ginkgo Bioworks's EPS (diluted) changed year-over-year?
- Ginkgo Bioworks's EPS (diluted) increased by 27.6% year-over-year, from -$1.96 to -$1.42.
- What is the long-term trend for Ginkgo Bioworks's EPS (diluted)?
- Over 4 years (2021 to 2025), Ginkgo Bioworks's EPS (diluted) has grown at a 42.0% compound annual growth rate (CAGR), from -$1.39 to -$5.65.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Ginkgo Bioworks's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude